600422.SHG KPC Pharmaceuticals Inc
- Market cap
- CNY 6.70B
- P/E
- -
- P/B
- 1.39x
- ROE
- -10.0%
- Dividend yield
- 3.39%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600422.SHG undervalued?
Graham numberThe Graham number of KPC Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KPC Pharmaceuticals Inc fundamental analysis
No fundamental analysis for KPC Pharmaceuticals Inc yet.
KPC Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as w…
Full company profileKPC Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KPC Pharmaceuticals Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.10B | 5.85B | 7.10B | 8.12B | 7.72B | 8.25B | 8.28B | 8.43B | 8.40B | 6.58B | 3.63B |
| Gross Profit | 1.97B | 2.63B | 3.54B | 3.94B | 3.31B | 3.39B | 3.43B | 3.89B | 3.63B | 2.53B | 785M |
| Operating Income | 424M | 412M | 420M | 540M | 541M | 634M | 497M | 790M | 928M | 449M | -308M |
| EBITDA | 588M | 530M | 564M | 711M | 729M | 832M | 705M | 981M | 1.13B | 638M | -519M |
| Net Income | 407M | 330M | 336M | 454M | 457M | 508M | 383M | 541M | 648M | 350M | -488M |
| EPS | 0.52 | 0.42 | 0.44 | 0.60 | 0.60 | 0.67 | 0.51 | 0.71 | 0.86 | 0.46 | -0.64 |
| Balance Sheet | |||||||||||
| Total Assets | 5.40B | 6.34B | 6.89B | 7.43B | 8.12B | 8.89B | 9.43B | 12.3B | 12.6B | 11.8B | 10.5B |
| Total Liabilities | 1.79B | 2.56B | 2.94B | 3.10B | 3.52B | 3.95B | 4.29B | 4.34B | 5.87B | 4.83B | 4.08B |
| Shareholders' Equity | 3.56B | 3.67B | 3.82B | 4.20B | 4.45B | 4.78B | 4.98B | 6.56B | 5.25B | 5.36B | 4.86B |
| Cash & Short-term Investments | 792M | 796M | 1.20B | 1.48B | 1.81B | 1.73B | 1.98B | 2.10B | 2.74B | 2.34B | 682M |
| Total Debt | 454M | 651M | 691M | 607M | 728M | 828M | 1.14B | 1.17B | 833M | 2.11B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 311M | 243M | 352M | 430M | 410M | 252M | 254M | 754M | 808M | 289M | - |
| Capital Expenditure | 203M | 269M | 217M | 347M | 159M | 236M | 102M | 110M | 79.4M | 90.6M | 125M |
| Free Cash Flow | 108M | -26.2M | 135M | 82.2M | 251M | 15.5M | 152M | 645M | 729M | 199M | -1.03B |
| Ratios | |||||||||||
| ROE | 11.4% | 9.0% | 8.8% | 10.8% | 10.3% | 10.6% | 7.7% | 8.2% | 12.3% | 6.5% | -10.0% |
| ROA | 7.5% | 5.2% | 4.9% | 6.1% | 5.6% | 5.7% | 4.1% | 4.4% | 5.1% | 3.0% | -4.6% |
| Net Profit Margin | 8.0% | 5.6% | 4.7% | 5.6% | 5.9% | 6.2% | 4.6% | 6.4% | 7.7% | 5.3% | -13.4% |
| Debt to Equity | 0.13x | 0.18x | 0.18x | 0.14x | 0.16x | 0.17x | 0.23x | 0.18x | 0.16x | 0.39x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
KPC Pharmaceuticals Inc dividends
- Dividend yield
- 3.39%
- Forward dividend
- 0.18 CNY
- Payout ratio
- 64.9%
- Ex-dividend date
- Jul 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 227M | 0.30 | 64.9% |
| 2024 | CNY 173M | 0.23 | 26.6% |
| 2023 | CNY 147M | 0.19 | 27.1% |
| 2022 | CNY 205M | 0.27 | 53.4% |
| 2021 | CNY 204M | 0.27 | 40.1% |
| 2020 | CNY 151M | 0.20 | 33.0% |
| 2019 | CNY 75.9M | 0.10 | 16.7% |
| 2018 | CNY 48.3M | 0.06 | 14.4% |
| 2017 | CNY 164M | 0.21 | 49.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on May 9, 2016.
Who owns KPC Pharmaceuticals Inc
- Insiders 38.37%
- Institutions 4.70%
- Public & others 56.93%
- Shares outstanding 757M
- Free float 470M
KPC Pharmaceuticals Inc company profile
- Company name
- KPC Pharmaceuticals Inc
- Ticker
- 600422.SHG
- ISIN
- CNE0000015P8
- Exchange
- Shanghai Stock Exchange
- Listed since
- Nov 16, 2000
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,072
- Fiscal year end
- December
- Address
- No.166 Keyi Road, Kunming, China, 650106
- Phone
- 86 871 6831 9868
- Website
- kpc.com.cn
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. The company offers products in the field of cardiovascular and cerebrovascular, orthopedics series, antimalarial, gynecology, digestive system, and others treatments. It offers its products under Luotai, Tianxuanqing, Artemedine, Artem, and Arco brands. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals,Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.
KPC Pharmaceuticals Inc management
9- Mr. Zhiqiang SunChief Financial Officer · born 1980
- Ms. Mengxun ZhangVP, Board Secretary & General Counsel · born 1978
- Mr. JunFeng LiuSenior Vice President · born 1977
- Ms. Li MengExecutive Vice President · born 1976
- Mr. Cheng SunVice President · born 1983
- Mr. Tong GaoVice President · born 1980
- Mr. Li Chun LiVice President · born 1982
- Mr. Jiang ZhongPresident · born 1976
- Mr. Lei SunHead of Accounting Department · born 1972